One such study involving mice bearing genetically engineered Kras G12D-/IL-17A-expressing lung tumors, clearly demonstrated dependence of both tumor progression and resistance to PD-1 targeted immunotherapy on neutrophil recruitment that was driven by tumor-derived IL–17A (Akbay et al., 2017). Here, KRAS is linked to neoplasm.